PIK3CA and breast carcinoma: Based on the results of the SOLAR-1 trial, alpelisib has been approved in combination with the fulvestrant for the treatment of PIK3CA-mutated, HR(hormone receptor)-positive, HER2(human epidermal growth factor receptor 2)-negative advanced breast cancer who had received endocrine therapy previously (12).